Prostatic Acid Phosphatase Is an Ectonucleotidase and Suppresses Pain by Generating Adenosine  by Zylka, Mark J. et al.
Neuron
ArticleProstatic Acid Phosphatase Is an Ectonucleotidase
and Suppresses Pain by Generating Adenosine
Mark J. Zylka,1,5,* Nathaniel A. Sowa,1,5 Bonnie Taylor-Blake,1 Margaret A. Twomey,1 Annakaisa Herrala,2
Vootele Voikar,3 and Pirkko Vihko2,4,*
1Department of Cell and Molecular Physiology, UNC Neuroscience Center, University of North Carolina, CB #7545, Chapel Hill,
NC 27599, USA
2Department of Biological and Environmental Sciences, Division of Biochemistry
3Neuroscience Center
P.O. Box 56, FI-00014, University of Helsinki, Finland
4Biocenter Oulu and Research Center for Molecular Endocrinology, P.O. Box 5000, FI-90014, University of Oulu, Finland
5These authors contributed equally to this work
*Correspondence: zylka@med.unc.edu (M.J.Z.), pirkko.vihko@helsinki.fi (P.V.)
DOI 10.1016/j.neuron.2008.08.024SUMMARY
Thiamine monophosphatase (TMPase, also known
as fluoride-resistant acid phosphatase) is a classic
histochemical marker of small-diameter dorsal root
ganglia neurons. The molecular identity of TMPase
is currently unknown. We found that TMPase is iden-
tical to the transmembrane isoform of prostatic acid
phosphatase (PAP), an enzymewith unknownmolec-
ular and physiological functions. We then found that
PAP knockout mice have normal acute pain sensitiv-
ity but enhanced sensitivity in chronic inflammatory
and neuropathic pain models. In gain-of-function
studies, intraspinal injection of PAP protein has
potent antinociceptive, antihyperalgesic, and antial-
lodynic effects that last longer than theopioid analge-
sicmorphine. PAP suppresses pain by functioning as
an ecto-50-nucleotidase. Specifically, PAP dephos-
phorylates extracellular adenosine monophosphate
(AMP) to adenosine and activates A1-adenosine re-
ceptors in dorsal spinal cord. Our studies reveal mo-
lecular and physiological functions for PAP in purine
nucleotide metabolism and nociception and suggest
a novel use for PAP in the treatment of chronic pain.
INTRODUCTION
Painful and tissue-damaging stimuli are sensed by small-diame-
ter nociceptive neurons located in the dorsal root ganglia (DRG)
and trigeminal ganglia (Woolf andMa, 2007). For nearly 50 years,
it was known that many small-diameter DRG neurons expressed
a histochemically identifiable acid phosphatase (Colmant, 1959),
commonly referred to as fluoride-resistant acid phosphatase
(FRAP) or thiamine monophosphatase (TMPase) (Dodd et al.,
1983; Knyihar-Csillik et al., 1986). TMPase dephosphorylates
diverse substrates, including the vitamin B1 derivative thiamine
monophosphate (TMP) and 50-nucleotide monophosphates
(Dodd et al., 1983; Sanyal and Rustioni, 1974; Silverman and
Kruger, 1988a).TMPase was intensively studied in the 1980s in an effort to
determine its molecular identity and function. TMPase marks
most nonpeptidergic DRG neurons, a subset of peptidergic
DRG neurons, and unmyelinated axon terminals in lamina II of
the dorsal spinal cord (Carr et al., 1990; Dalsgaard et al., 1984;
Dodd et al., 1983; Hunt and Rossi, 1985; Knyihar-Csillik et al.,
1986; Nagy andHunt, 1982; Silverman andKruger, 1988a). Since
peptidergic and nonpeptidergic neurons are generally consid-
ered to be nociceptive (Woolf and Ma, 2007), these anatomical
studies suggested that TMPase might function in nociception.
Moreover, TMPase staining in lamina II of spinal cord is reduced
or eliminated when peripheral nerves are damaged (Colmant,
1959; Csillik and Knyihar-Csillik, 1986; Shields et al., 2003;
Tenser, 1985; Tenser et al., 1991). Ultimately, studies of TMPase
waned when it was found that isolectin B4 (IB4) colocalized with
TMPase and was an easier-to-use marker of nonpeptidergic
neurons (Silverman and Kruger, 1988b, 1990). More importantly,
the gene encoding TMPase was never identified, making it
impossible to study the molecular and physiological function of
TMPase in sensory neurons.
In an attempt to identify the TMPase gene, Dodd and co-
workers partially purified TMPase protein from rat DRG using
chromatography (Dodd et al., 1983). The partially purified rat pro-
tein was inhibited by the nonselective acid phosphatase inhibitor
L(+)-tartrate and was similar in molecular weight to the secretory
isoform of human prostatic acid phosphatase (PAP, also known
as ACPP), the only known isoform of PAP at the time (Ostrowski
and Kuciel, 1994). These biochemical experiments hinted that
TMPase might be secretory PAP (Dodd et al., 1983). However,
subsequent studies using anti-PAP antibodies failed to immuno-
stain small-diameter DRG neurons and their axon terminals in
lamina II (i.e., the neurons and axons that contain TMPase)
(Dodd et al., 1983; Silverman andKruger, 1988a). As summarized
by Silverman and Kruger in 1988, these data made it impossible
to determine whether TMPase was PAP or some other enzyme.
In light of this unsolved question regarding the molecular na-
ture of TMPase and the historical use of TMPase as a nociceptive
neuron marker, we sought to definitively identify the TMPase
gene and ascertain its function in nociception. Our experiments
revealed that TMPase was a recently discovered transmem-
brane (TM) isoform of PAP (TM-PAP) (Quintero et al., 2007) andNeuron 60, 111–122, October 9, 2008 ª2008 Elsevier Inc. 111
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PAP Suppresses Pain by Generating AdenosineFigure 1. DRG Neurons Express the Trans-
membrane Isoform of PAP
(A) Secreted and transmembrane isoforms of PAP.
Both isoforms have identical N-terminal regions,
including the signal peptide (SP) and extracellular
catalytic acid phosphatase domain. Alternative
splicing at the last intron-exon junction (arrow) re-
sults in the inclusion or exclusion of a transmem-
brane (TM) domain.
(B and C) In situ hybridization of mouse lumbar
DRG with riboprobes complementary to the
unique 30 untranslated regions of (B) the trans-
membrane isoform or (C) the secreted isoform.
Scale bar, 50 mm in (B) and (C).was not the secretory isoform of PAP. This molecular identifica-
tion then allowed us to use modern molecular and genetic
approaches to rigorously study the function of PAP/TMPase in
nociceptive circuits. Using our PAP knockout mice, we found
that deletion of PAP increased thermal hyperalgesia (increased
pain sensitivity) and mechanical allodynia in animal models of
chronic pain. Conversely, a single intraspinal injection of PAP
protein had antinociceptive, antihyperalgesic, and antiallodynic
effects that lasted for up to 3 days, much longer than a single
injection of the commonly used opioid analgesic morphine.
Mechanistically, we found that PAP is an ectonucleotidase that
dephosphorylates extracellular AMP to adenosine and requires
A1-adenosine receptors (A1Rs) for antinociception.
PAP has been intensively studied for 70 years in the prostate
cancer field (Gutman and Gutman, 1938). Despite decades of
research, the molecular and physiological functions for PAP re-
mained unknown. Our studies with pain-sensing neurons identify
the in vivo substrate, the molecular mechanism, and the physio-
logical function for this medically relevant protein. Moreover, we
show that PAP functions in nociception. Considering that
TM-PAP is expressed throughout the body (Quintero et al.,
2007), PAP could regulate diverse physiological processes that
are dependent on adenosine (Jacobson and Gao, 2006).
RESULTS
Prostatic Acid Phosphatase Is TMPase in Dorsal
Root Ganglia Sensory Neurons
In rats, mice, and humans, PAP is expressed as a secreted pro-
tein or as a type 1 transmembrane (TM) protein, with the catalytic
acid phosphatase domain localized extracellularly (Figure 1A)
(Quintero et al., 2007; Roiko et al., 1990; Vihko, 1979). The secre-
tory isoform has been used as a diagnostic marker for prostate
cancer for nearly 70 years, whereas the TM isoform was only re-
cently discovered (Gutman and Gutman, 1938; Quintero et al.,
2007). To determine whether either PAP isoform is expressed
in DRG, we performed in situ hybridization with isoform-specific
antisense riboprobes. These experiments revealed that TM-PAP
was expressed in a subset of small-diameter DRG neurons
(Figure 1B), while the secretory isoform was expressed at low-
to-undetectable levels (Figure 1C). Importantly, TM-PAP is local-
ized to the plasmamembrane and vesicular membranes, just like
TMPase (Csillik and Knyihar-Csillik, 1986; Quintero et al., 2007).
We also found that PAP was expressed in human DRG using112 Neuron 60, 111–122, October 9, 2008 ª2008 Elsevier Inc.RT-PCR and intron-spanning primers (data not shown), consis-
tent with localization of TMPase to small-diameter human DRG
neurons (Silverman and Kruger, 1988a).
To directly test whether PAP had TMPase histochemical activ-
ity, we overexpressed mouse TM-PAP in HEK293 cells, then
stained these cells using TMP histochemistry. Cells transfected
with TM-PAP were heavily stained when the plasma membrane
was left intact (Figure 2A), indicating that TM-PAP can dephos-
phorylate TMP extracellularly. TMPase staining was even greater
when the plasma membrane was permeabilized with detergent
(Figure S1H available online). In contrast, control cells trans-
fected with empty vector were not stained (Figure 2B). Two
additional phosphatases (soluble acid phosphatase 1 [ACP1]
and placental alkaline phosphatase) lacked TMPase activity
(Figure S1).
DRG neurons express at least eight different acid phospha-
tase genes (M.J.Z, unpublished data), any one of which could
be TMPase. To determine whether PAP was the only enzyme
in sensory neurons capable of dephosphorylating TMP, we ana-
lyzed DRG and spinal cord tissues from PAPD3/D3 (henceforth
referred to as PAP/) knockout mice (P.V. et al., abstract from
Proceedings of the AACR, 2005, 96th Annual Meeting, Anaheim,
CA). In these mice, deletion of exon 3 causes complete loss of
secretory and transmembrane PAP catalytic activity (P.V. et al.,
abstract from Proceedings of the AACR, 2005). Strikingly, TMP
histochemical staining of DRG neurons and axon terminals in
spinal cord was abolished in PAP/ mice (Figures 2C–2F).
Absence of TMP staining in PAP/ mice was not due to devel-
opmental loss of DRG neurons, as wild-type and PAP/ mice
had equivalent numbers of P2X3-expressing neurons relative
to all NeuN+ neurons in lumbar ganglia (43.4% ± 1.9% verses
42.4% ± 1.9% (SEM); 1500 NeuN+ neurons counted per geno-
type). P2X3 is an ATP-gated ion channel that is colocalized
with PAP (see below). Moreover, loss of TMPase staining in the
spinal cord was not due to loss of axon terminals in the dorsal
horn (Figure S2). These gain- and loss-of-function experiments
conclusively prove that TMPase in small-diameter DRG neurons
is the transmembrane isoform of PAP.
In addition, by combining immunofluorescence and TMP
histochemistry, we observed colocalization between PAP and
TMPase in DRG neurons (Figures S3A–S3C) and in axon termi-
nals in lamina II of the spinal cord (Figures S3D–S3F). This anti-
PAP antibody did not stain DRG or spinal cord sections from
PAP/ mice, confirming antibody specificity.
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published microarray data sets that measured changes in gene
expression in DRG following peripheral nerve injury (Costigan
et al., 2002; Davis-Taber, 2006). In both studies, PAP was one
of the most heavily downregulated genes. This is consistent
with the fact that TMPase histochemical activity is greatly re-
duced in DRG and dorsal horn after peripheral nerve injury
(Colmant, 1959; Csillik and Knyihar-Csillik, 1986; Shields et al.,
2003; Tenser, 1985; Tenser et al., 1991).
PAP Is Primarily Expressed in Nonpeptidergic
DRG Neurons
TMPase was previously localized to nonpeptidergic DRG neu-
rons and a small number of peptidergic neurons (Carr et al.,
1990; Dalsgaard et al., 1984; Hunt and Mantyh, 2001; Nagy
and Hunt, 1982; Silverman and Kruger, 1988b). To show that
PAP had a similar distribution and to identify additional proteins
that were colocalized with PAP, we performed double-label
Figure 2. PAPDephosphorylates TMP in HEK293 Cells and Nocicep-
tive Circuits
(A) HEK293 cells were transfected with amouse TM-PAP expression construct
or (B) with empty pcDNA3.1 vector and then stained using TMP histochemis-
try. The plasma membrane was not permeabilized, so that extracellular phos-
phatase activity could be assayed. (C and D) Lumbar DRG and (E and F) spinal
cord fromwild-type and PAP/ adult mice stained using TMP histochemistry.
Identical results were obtained from 14 additional mice of each genotype. TMP
(6 mM) was used as substrate, and buffer pH was 5.6 in all panels. Scale bar,
50 mm in (A)–(D), 500 mm in (E) and (F).immunofluorescence with our anti-PAP antibody and various
sensory neuron markers. Cell counts from confocal images re-
vealed that virtually all nonpeptidergic DRG neurons, as defined
by the markers IB4, Mrgprd-EGFPf, and P2X3, coexpressed
PAP (Figures 3A–3I and Table S1). Moreover, PAP+ axons termi-
nated in lamina II of spinal cord in association with nonpeptider-
gic neuron markers (Figures S4A–S4F). In contrast, a smaller
percentage (17.1%) of peptidergic CGRP+ neurons (n = 1364
cells counted) expressed PAP (Figures 3J–3L and Table S1),
and there was minimal overlap between PAP+ and peptidergic
(CGRP+) axon terminals in spinal cord (Figures S4G–S4I). Finally,
19.1% ± 1.3% of PAP+ neurons expressed the capsaicin and
noxious heat receptor TRPV1 (Figures 3M–3O). Taken together,
Figure 3. PAP Is Primarily Expressed in Nonpeptidergic Neurons
(A–O) Mouse L4–L6 DRG neurons were stained with antibodies against various
sensory neuron markers (green) and with antibodies against PAP (red). Tissue
from adult MrgprdDEGFPf mice was used to identify Mrgprd-expressing
neurons. Arrowheads mark examples of double-labeled cells. Images were
acquired by confocal microscopy. Scale bar (bottom right panel), 50 mm for
all panels.Neuron 60, 111–122, October 9, 2008 ª2008 Elsevier Inc. 113
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PAP Suppresses Pain by Generating AdenosineFigure 4. PAP/Mice Show Enhanced No-
ciceptive Responses following Inflamma-
tion and Nerve Injury
(A and B) CFA inflammatory pain model. Wild-type
and PAP/ mice were tested for (A) thermal
sensitivity using a radiant heat source and (B) me-
chanical sensitivity using an electronic von Frey
semiflexible tip before (baseline, BL) and following
injection of CFA (CFA-arrow) into one hindpaw.
The noninflamed hindpaw served as control.
(C and D) SNI neuropathic pain model. The sural
and common peroneal branches of the sciatic
nerve were ligated and then transected (Injure-
arrow). Injured and noninjured (control) hindpaws
were tested for (C) thermal and (D) mechanical
sensitivity.
(A–D) Paired t tests were used to compare
responses at each time point between wild-type
(n = 10) and PAP/mice (n = 10); same paw com-
parisons. *p < 0.05, **p < 0.005, ***p < 0.0005. All
data are presented as means ± SEM.these confocal imaging studies revealed that PAP was preferen-
tially expressed in nonpeptidergic, presumably nociceptive,
DRG neurons.
Chronic Pain-Induced Thermal Hyperalgesia
and Mechanical Allodynia Are Enhanced
in PAP Knockout Mice
PAP was generally thought to function only in the prostate
(Ostrowski andKuciel, 1994). However, our expression data sug-
gested that PAP might also function in nociceptive neurons. To
evaluate pain-related functions for PAP, we tested age-matched
wild-type C57BL/6 and PAP/ male mice (backcrossed to
C57BL/6 for ten generations) using acute and chronic pain be-
havioral assays. We found no significant differences between
genotypes using a measure of mechanical sensitivity (electronic
von Frey) or several different measures of acute noxious thermal
sensitivity (Table S2). In contrast, PAP/ mice showed signifi-
cantly greater thermal hyperalgesia and mechanical allodynia
relative to wild-type mice in the complete Freund’s adjuvant
(CFA) model of chronic inflammatory pain (Figures 4A and 4B).
In addition, PAP/ mice showed significantly greater thermal
hyperalgesia in the spared nerve injury (SNI) model of neuro-
pathic pain (Figures 4C and 4D) (Shields et al., 2003).
PAP Has Potent and Long-Lasting
Antinociceptive Properties
Since deletion of PAP enhanced sensitivity in two different
models of chronic pain, we hypothesized that excessPAP should
have the opposite effect and reduce pain. To test this, we took
advantage of the fact that secretory PAP protein is commercially
available and has the same N-terminal catalytic region as
TM-PAP (Figure 1A). We injected wild-type mice intrathecally
(i.t.) into the lumbar region of spinal cord with pure human
(h)PAPprotein (the secretory isoform).Controlmicewere injected
i.t. with an equivalent amount of heat-denatured, and hence114 Neuron 60, 111–122, October 9, 2008 ª2008 Elsevier Inc.phosphatase-inactive, hPAP protein. In all cases, we determined
that hPAP was active or inactive using a sensitive fluorometric-
based phosphatase assay (see Experimental Procedures). We
then measured noxious thermal and mechanical sensitivity
before (baseline, BL) and after hPAP injections (Figures 5A and
5B). Six hours after i.t. injection of hPAP, paw-withdrawal latency
to a noxious thermal stimulus significantly increased relative to
controls and remained elevated for 3 days (Figure 5A). This anti-
nociceptive effect was dose dependent (Figure S5) and required
PAP catalytic activity (Figure 5A). Active hPAP did not alter
mechanical sensitivity (Figure 5B) nor did it cause paralysis or
sedation. This long-lasting antinociceptive effect was species
conserved, as a single i.t. injection of bovine (b)PAP also in-
creased thermal withdrawal latency for 2 days but had no effect
on mechanical sensitivity (Figure S6). Finally, i.t. injection of an
unrelated protein (bovine serum albumin) or large quantities of
a different secreted phosphatase (bovine alkaline phosphatase)
did not alter thermal ormechanical sensitivity (FiguresS6andS7).
We next used the same behavioral assay to compare PAP
antinociception to the commonly used opioid analgesic mor-
phine. We found that PAP and morphine antinociception were
similar in magnitude following a single i.t. injection (40.8% ±
3.3% versus 62.2% ± 9.9% increase above baseline at the high-
est doses, respectively) but that PAP antinociception lasted
much longer than morphine (3 days verses 5 hr at the highest
doses, respectively; Figures S5 and S8). Similarly, Grant and
colleagues found that the same high dose of morphine (50 mg,
i.t., single injection) lasted 4.6 ± 1.0 hr in mice (Grant et al., 1995).
We next evaluated the extent to which hPAP affected hyperal-
gesia and allodynia in the CFA model of inflammatory pain and
the SNI model of neuropathic pain. For both chronic pain assays,
we used the uninjured paw as control. Strikingly, in both chronic
pain models, a single i.t. injection of active hPAP was antihyper-
algesic and antiallodynic in the inflamed/injured paw (Figures
5C–5F). As before, a single injection was effective for several
Neuron
PAP Suppresses Pain by Generating Adenosinedays, and phosphatase activity was required for these antinoci-
ceptive effects.
Since PAP/ mice showed enhanced hyperalgesia and allo-
dynia in the CFA inflammatory pain model (Figures 4A and 4B),
we next testedwhether hPAP could rescue these enhanced ther-
mal and mechanical phenotypes in PAP/ mice. We found that
i.t. injection of hPAP increased thermal withdrawal latency in the
control paw ofPAP/mice to the same extent aswild-typemice
(Figure 6A, blue lines). This demonstrated thatPAP/mice were
competent to respond to acute increases in PAP activity. Strik-
ingly, injection of hPAP rescued the thermal and mechanical in-
flammatory pain phenotype in the inflamed paw of PAP/ mice
(Figures 6A and 6B, compare red lines where PAP was injected
to black lines where inactive PAP was injected). Importantly,
these data also suggest that localized, spinal injection of hPAP
can rescue the behavioral deficit caused by deletion of PAP
throughout the animal.
PAP Suppresses Pain by Generating Adenosine,
a Known Analgesic in Mammals
The antinociceptive effects of PAP require catalytic activity. This
suggested PAP might generate, via dephosphorylation, a mole-
cule that regulates nociceptive neurotransmission in the spinal
cord. PAP and TMPase can dephosphorylate many different
substrates (Dziembor-Gryszkiewicz et al., 1978; Sanyal and
Figure 5. hPAP Protein Has Long-Lasting
Antinociceptive Effects when Injected Intra-
spinally
(A and B) Wild-type mice were tested for (A)
thermal and (B) mechanical sensitivity before
(baseline, BL) and following i.t. injection of active
or inactive hPAP (hPAP-arrow).
(C and D) CFA inflammatory pain model. CFA was
injected into one hindpaw (CFA-arrow). Active or
inactive hPAP was i.t. injected 1 day later (hPAP-
arrow). Inflamed and noninflamed (control) hind-
paws were tested for (C) thermal and (D) mechan-
ical sensitivity.
(E and F) SNI neuropathic pain model. The sural
and common peroneal branches of the sciatic
nerve were ligated and then transected (Injure-
arrow). Active or inactive hPAP was i.t. injected
6 days later (hPAP-arrow). Injured and noninjured
(control) hindpaws were tested for (E) thermal
and (F) mechanical sensitivity.
(A–F) 250 mU hPAP injected per mouse. Paired t
tests were used to compare responses at each
time point between mice injected with active
hPAP (n = 10 mice per experiment) to mice in-
jected with heat-inactivated hPAP (n = 10 mice
per experiment); same paw comparisons.
*p < 0.05, **p < 0.005, ***p < 0.0005. All data are
presented as means ± SEM.
Rustioni, 1974; Silverman and Kruger,
1988b; Vihko, 1978). We focused on
AMP because dephosphorylation of
AMP produces adenosine—a molecule
that inhibits nociceptive neurotransmis-
sion in spinal cord slices and has well-studied analgesic proper-
ties in mammals (Li and Perl, 1994; Liu and Salter, 2005; Post,
1984; Sawynok, 2006).
At the time we began our studies, there was no direct proof
that PAP or TMPase could generate adenosine from AMP. In-
stead, production of adenosine was inferred by measuring
production of inorganic phosphate (Vihko, 1978). To directly
test whether PAP could generate adenosine from AMP and other
adenine nucleotides, we incubated PAPwith 1mMAMP, ADP, or
ATP at pH 7.0 for 4 hr. We then detected adenine nucleotides
and adenosine using high-performance liquid chromatography
(HPLC) and UV absorbance (Lazarowski et al., 2004). These
studies revealed that PAP can rapidly dephosphorylate AMP
and, to a much lesser extent, ADP to adenosine (Figures 7A
and 7B). Importantly, no unexpected peaks were seen in the
chromatograms (Figure 7B, data not shown), ruling out the
possibility that PAP had additional hydrolytic activities toward
nucleotides.
Next, we tested the extent to which PAP could dephosphory-
late extracellular AMP in HEK293 cells, DRG neurons, and spinal
cord using AMP enzyme histochemistry. HEK293 cells trans-
fected with TM-PAP were heavily stained, whereas control cells
were not (Figures 7C and 7D), highlighting that TM-PAP dephos-
phorylates extracellular AMP and hence has ecto-50-nucleo-
tidase activity. In addition, small-diameter DRG neurons fromNeuron 60, 111–122, October 9, 2008 ª2008 Elsevier Inc. 115
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neurons had weak granular cytoplasmic staining. In contrast,
only weak granular staining was present in DRG neurons from
PAP/ mice (Figures 7E and 7F). These data indicate that
PAP is the predominant ecto-50-nucleotidase on the soma of
small-diameter neurons. Finally, AMP histochemical staining of
axon terminals in lamina II was reduced in PAP/ relative to
wild-type mice, but was not eliminated (Figures 7G and 7H).
This indicates that PAP is one of perhapsmany enzymes in spinal
cord with the ability to dephosphorylate AMP to adenosine.
Adenosine mediates antinociception through Gi-coupled
A1-adenosine receptors (A1Rs) (Lee and Yaksh, 1996; Sawynok,
2006). To directly test whether A1Rs were required for PAP anti-
nociception, we next i.t. injected hPAP into wild-type C57BL/6
and A1-adenosine receptor knockout mice (A1R
/, Adora1/;
backcrossed to C57BL/6 mice for 12 generations), then mea-
sured noxious thermal and mechanical sensitivity (Hua et al.,
2007; Johansson et al., 2001). Strikingly, hPAP increased ther-
mal paw-withdrawal latency for 3 days in wild-type mice but
was without effect in A1R
/ mice (Figure 8A). Similarly, bPAP
increased paw-withdrawal latency to the noxious thermal stimu-
lus in wild-typemice but had no effect inA1R
/mice (Figure S9).
As expected, hPAP did not affect mechanical sensitivity in
uninjured animals (Figure 8B).
We next tested wild-type and A1R
/ mice using the CFA
chronic inflammatory pain model and the SNI neuropathic pain
model. Reproducing previous findings (Wu et al., 2005), A1R
/
mice showed greater thermal hyperalgesia compared to wild-
type mice after CFA injection and after nerve injury (but before
PAP injection; Figures 8C and 8E). Following i.t. injection of
hPAP, thermal and mechanical thresholds increased in the in-
flamed/injured paws of wild-type mice but not in A1R
/ mice
(Figures 8C–8F). Likewise, the selective A1R antagonist 8-cyclo-
pentyl-1, 3-dipropylxanthine (CPX; 1 mg/kg, i.p.) transiently
reversed the antinociceptive effects of hPAP in control and
inflamed hindpaws (Figure S10). Conversely, injection (i.t.) of
the selective A1R agonist N
6-cyclopentyladenosine (CPA) into
wild-type mice produced dose-dependent increases in paw-
withdrawal latency to our thermal stimulus (Figure S11), similar
to i.t. hPAP. However, unlike hPAP, CPA had short-term effects
(lasting hours not days) and CPA caused transient paralysis at
the two highest doses. When taken together, our results demon-
strate that the antinociceptive effects of PAP are due to genera-
tion of adenosine followed by activation of A1Rs. Moreover, our
data demonstrate an in vivo function for PAP as an ectonucleo-
tidase.
DISCUSSION
For 70 years, PAP was thought to be a secreted protein found
only in the prostate and was used as a diagnostic marker for
prostate cancer (Gutman and Gutman, 1938; Ostrowski and
Kuciel, 1994). Despite years of research, little was known about
how PAP functioned in vivo at a mechanistic level or which PAP
substrate was most biologically relevant. In biochemical assays,
PAP can dephosphorylate diverse substrates, including
b-glycerophosphate, lysophosphatidic acid, phospho-amino
acids, and 50-nucleotides (Dziembor-Gryszkiewicz et al., 1978;
Li et al., 1984; Porvari et al., 1994; Tanaka et al., 2004; Vihko,
1978).
In our efforts to solve an old and unanswered question in the
pain field, we found that PAP was expressed in nociceptive
neurons, was antinociceptive, and functioned as an ectonucleo-
tidase. Importantly, we found that the in vivo effects of PAP were
eliminated by deletion of one gene, the A1-adenosine receptor.
This makes it unlikely that PAP suppresses pain by generating
any othermolecules besides adenosine. Moreover, the in vivo ef-
fects of PAP on acute and chronic pain mimic the effects of i.t.
adenosine and A1R agonists (Figure S11) (Liu and Salter, 2005;
Sawynok, 2006). Notably, both PAP and adenosine receptor
agonists have antiallodynic and antihyperalgesic properties in
animal models of inflammatory and neuropathic pain, both
have a long (>24 hr) duration of action after a single i.t. injection,
and both lose their ability to suppress pain in A1R
/ mice or
following injection of A1R antagonists (Belfrage et al., 1999; Cui
et al., 1997; Eisenach et al., 2002; Gomes et al., 1999; Johansson
et al., 2001; Lavand’homme and Eisenach, 1999; Lee and Yaksh,
1996;Maione et al., 2007; Poon and Sawynok, 1998). In addition,
both A1R
/ and PAP/ mice show enhanced thermal hyperal-
gesia, but not enhanced allodynia, in neuropathic pain models
(Figures 4C and 4D) (Wu et al., 2005). This shared modality-
selective phenotype further supports our conclusion that endog-
enous PAP works via A1R activation. Although our studies were
focused on nociceptive neurons, PAP is expressed inmany other
tissues (Quintero et al., 2007) and thus could function as an ec-
tonucleotidase throughout the body.
Figure 6. Intraspinal PAP Has Antinocicep-
tive Effects in PAP/ Mice and Rescues
the Chronic Inflammatory Pain Behavioral
Phenotype in PAP/ Mice
Wild-type and PAP/ mice were tested for (A)
thermal sensitivity and (B) mechanical sensitivity
before (baseline, BL) and following injection of
CFA (CFA-arrow) into one hindpaw. The nonin-
flamed hindpaw served as control. One day later,
half of the wild-type and PAP/ mice were in-
jected with active hPAP (hPAP-arrow; 250 mU,
i.t.; red and blue lines) while the other half were in-
jected with inactive hPAP (black lines). Note: Data
from these inactive hPAP-injected mice were pre-
sented in Figures 4A and 4B. Paired t tests were used to compare responses at each time point between wild-type (n = 10/group) andPAP/mice (n = 10/group);
same paw comparisons (n = 40 mice were used for this experiment). *p < 0.05, **p < 0.005, ***p < 0.0005. All data are presented as means ± SEM.116 Neuron 60, 111–122, October 9, 2008 ª2008 Elsevier Inc.
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Effects when Compared to Opioid Analgesics
Morphine and other opioids are powerful analgesics but have
side effects that limit their long-term use. We found that a single
Figure 7. PAP Has Ecto-50-Nucleotidase Activity, as Revealed by
Dephosphorylation of AMP to Adenosine In Vitro, in Cells and in
Nociceptive Circuits
(A) hPAP (2.5 U/ml) was incubated with 1 mM AMP, ADP, or ATP. Reactions
(n = 3 per time point) were stopped by heat denaturation at the indicated times.
Conversion of nucleotides to adenosine was measured by HPLC. Data are
presented as means ± SEM.
(B) HPLC chromatogram before (t = 0) and after (t = 240 min) incubation of
1 mM AMP with hPAP. Peaks corresponding to adenosine (ado) and AMP
are indicated. Arbitrary units (a.u.).
(C) HEK293 cells were transfectedwith amouse TM-PAP expression construct
or (D) with empty pcDNA3.1 vector and then stained using AMP histochemis-
try. The plasma membrane was not permeabilized, so that extracellular phos-
phatase activity could be assayed.
(E and F) Lumbar DRG and (G and H) spinal cord from wild-type and PAP/
adult mice stained using AMP histochemistry. Motor neurons in the ventral
horn of wild-type and PAP/ spinal cord were also stained. Identical results
were obtained from five additional mice of each genotype.
AMP (6 mM in [C] and [D] and 0.3 mM in [E]–[H]) was used as substrate, and
buffer pH was 5.6. Scale bar, 50 mm in (C)–(F), 500 mm in (G) and (H).i.t. injection of hPAP (250mU) produced an increase in paw-with-
drawal latency of 40.8%±3.3% (relative to baseline; n = 74mice)
in the Hargreaves test (Figure S5C) and reproducibly lasted for
3 days (Figures 5, 6, 8, S5A, and S10). Using the same behavioral
test, we found that 1 mg and 10 mg of morphine produced an in-
crease in paw-withdrawal latency of 24.9% ± 5.3% and 55.9% ±
13.7%, respectively, but lasted 1–4 hr in mice (Figure S8). Sim-
ilarly, others found that 1 mg and 10 mg of morphine (i.t., single
dose) produced an increase in paw-withdrawal latency of 36%
and 60%, respectively (Dirig and Yaksh, 1995), that lasted hours
in rats (Nishiyamaet al., 2000; Zhanget al., 2005). Higher dosesof
i.t. morphine causemotor impairment and death (Figure S8) (Dirig
and Yaksh, 1995; Grant et al., 1995; Nishiyama et al., 2000). Al-
though high doses of A1R agonists also cause motor impairment
(Figure S11) (Sawynok, 2006), we found no such side-effects at
the highest dose of PAP tested. These comparisons reveal that
the magnitude of PAP and morphine antinociception is similar;
however, PAP antinociception lasts substantially longer. In fact,
using area under the curve (AUC) measurements that integrate
magnitude of antinociception over time, the 250 mU dose of
hPAP is eight times more effective than the highest dose of
morphine tested (Figures S5B and S8B). These long-lasting and
A1R-dependent antinociceptive effects of PAP are supported
by previous studies showing that adenosine produces long-
duration (>24 hr) analgesia in humans and rodents (Belfrage
et al., 1999; Eisenach et al., 2002; Lavand’homme and Eisenach,
1999). Finally, we found that PAP antinociception could be
transiently inhibited with an A1R antagonist (Figure S10). This
suggests that PAP is stable in spinal cord following injection
and is capable of producing adenosine for days. Likewise,
PAP has a very long (11.7 day) half-life in blood (Vihko
et al., 1982).
PAP Is an Ectonucleotidase in Nociceptive Circuits
Nucleotides like ATP and ADP play key roles in pain mechanisms
(Burnstock, 2007; Sawynok, 2006; Tozaki-Saitoh et al., 2008;
Tsuda et al., 2005). Nucleotides are released extracellularly by
stimulated sensory neurons and activate purinergic P2X and
P2Y receptors on neurons and microglia. Activation of these re-
ceptors facilitates neurotransmission, sensitizes neurons, and
causes pain. The excitatory effects of extracellular nucleotides
can be terminated by several membrane-bound and, in some
cases, secreted ectonucleotidases. These ectonucleotidases
dephosphorylate extracellular ATP, ADP, and AMP to adenosine
(Zimmermann, 2006). While ATP has excitatory effects and
causes pain, adenosine has inhibitory effects and suppresses
pain (Nakagawa et al., 2007; Sawynok, 2006).
One or more ectonucleotidases were known to exist in noci-
ceptive circuits (Nagy and Daddona, 1985; Scott, 1967; Suran,
1974). Considering the key roles nucleotides and adenosine
play in pain mechanisms, it is surprising to note that none of
these ectonucleotidases have beenmolecularly identified. Using
electrophysiological approaches, two groups found that appli-
cation of ATP, ADP, or AMP inhibited postsynaptic neurons in
the dorsal spinal cord indirectly via metabolic conversion to
adenosine (Li and Perl, 1995; Salter and Henry, 1985). Likewise,
Patterson and colleagues used indwelling microprobes and
found that adenosine was metabolically generated in vivoNeuron 60, 111–122, October 9, 2008 ª2008 Elsevier Inc. 117
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PAP Suppresses Pain by Generating Adenosinewhen the dorsal spinal cord was perfused with AMP (Patterson
et al., 2001). Dephosphorylation of AMP to adenosine was
partially blocked by coperfusion with a,b-methylene-ADP (Pat-
terson et al., 2001), an inhibitor of ecto-50-nucleotidase (CD73).
This enzyme has not yet been molecularly characterized in
DRG neurons or spinal cord.
Our studies clearly show that PAP is expressed in small-diam-
eter DRG neurons, that PAP dephosphorylates AMP to adeno-
sine in vitro, in heterologous cells, in DRG neurons, and in lamina
II of the spinal cord, and that PAP antinociception requires
A1Rs. To our knowledge, none of the known ectonucleotidases
(Zimmermann, 2006) have been studied at this level of detail in
nociceptive circuits. Collectively, our studies define PAP as an
ectonucleotidase in nociceptive circuits.
PAP Is Well Localized to Modulate A1-Adenosine
Receptors in Spinal Cord Lamina II
Our data highlight a close functional relationship between PAP
and A1Rs. This raises the question of where PAP acts to modu-
late A1Rs and nociceptive behaviors. Within the spinal cord,
A1Rs are concentrated in lamina II, particularly on postsynaptic
neurons that are in close contact with IB4+ axon terminals, but
not in close contact with CGRP+ axon terminals (Schulte et al.,
2003). A1Rs are also found presynaptically in small- to me-
dium-diameter DRG neurons, and possibly in the axon terminals
Figure 8. PAP Requires A1-Adenosine Re-
ceptors for Antinociception
(A and B) Wild-type and A1R
/ mice were tested
for (A) thermal and (B) mechanical sensitivity
before (baseline, BL) and following i.t. injection of
hPAP (hPAP-arrow).
(C and D) CFA was injected into one hindpaw
(CFA-arrow) of wild-type and A1R
/ mice. Active
or inactive hPAP was i.t. injected 1 day later
(hPAP-arrow). Inflamed and noninflamed (control)
hindpaws were tested for (C) thermal and (D)
mechanical sensitivity.
(E and F) The SNI model was used to induce
neuropathic pain (Injure-arrow) in wild-type and
A1R
/ mice. Active or inactive hPAP was i.t.
injected 4 days later (hPAP-arrow). Injured and
noninjured (control) hindpaws were tested for (E)
thermal and (F) mechanical sensitivity. For all ex-
periments, 250 mU hPAP was injected per mouse.
t tests were used to compare responses at each
time point between wild-type (n = 10) and A1R
/
mice (n = 9); same paw comparisons. *p < 0.05,
**p < 0.005, ***p < 0.0005. All data are presented
as means ± SEM.
of these neurons (based on accumulation
of A1Rs proximal to dorsal root ligature)
(Schulte et al., 2003). In addition, A1R
activation inhibits presynaptic glutamate
release primarily from unmyelinated ter-
minals and inhibits postsynaptic neurons
in the substantia gelatinosa (lamina II) of
spinal cord (Lao et al., 2001; Li and Perl,
1994; Patel et al., 2001).
Considering that virtually all PAP+ neurons and axons are IB4+
(Table S1) and terminate in lamina II (Figure S4), this makes PAP
well localized to generate extracellular adenosine and modulate
A1Rs on presynaptic terminals and on postsynaptic neurons in
the IB4-binding region of lamina II. In addition, PAP (TMPase)
is enriched on the presynaptic membranes of DRG neurons at
the level of electron microscopy (Knyihar-Csillik et al., 1986)
and has a broad pH optimum (pH 3–8) (Van Etten, 1982), making
PAP capable of generating adenosine locally at synapses.
Further support for a central site of action comes from the fact
that dephosphoryation of extracellular AMP in lamina II is re-
duced in PAP/mice and PAP is antinociceptive when injected
intraspinally. Moreover, central injection of PAP can rescue
behavioral deficits caused by deletion of PAP throughout the
animal (Figure 6).
Although our data clearly support a central mechanism of
action, we cannot exclude the possibility that PAP might also
generate adenosine peripherally to mediate antinociception.
Peripheral administration of adenosine has long-lasting antinoci-
ceptive and analgesic effects in rodents and humans, just like
central administration (Hayashida et al., 2005; Sawynok, 2006).
We detected PAP on axons in the dermis of the skin; however,
our antibody was not sensitive enough to detect PAP on axon
terminals in epidermis (B.T-B. and M.J.Z, unpublished). More-
over, others found that TMPase (PAP) accumulated proximal to118 Neuron 60, 111–122, October 9, 2008 ª2008 Elsevier Inc.
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PAP Suppresses Pain by Generating Adenosinea ligature of the sural nerve, suggesting that PAP is transported
peripherally (McMahon and Moore, 1988).
Physiological Function of PAP throughout
the Body—Insights from Pain-Sensing Neurons
In prostate, PAP is thought to function as a tumor suppressor.
Notably, prostate cancer cell growth rate is reducedwhen secre-
tory hPAP (referred to as ‘‘cellular’’ PAP by the authors) is over-
expressed (Lin et al., 1992;Meng and Lin, 1998; Veeramani et al.,
2005). Conversely, deletion of PAP (secreted and TM isoforms) in
mice leads to prostate hyperplasia followed by prostate cancer
(P.V. et al., abstract from Proceedings of the AACR, 2005). The
mechanism by which PAP mediates growth suppression is, at
present, unclear. Correlative data from Lin and colleagues sug-
gests that secretory (‘‘cellular’’) PAP regulates growth directly
by dephosphorylating phosphotyrosine residues in the cytoplas-
mic tail of ErbB2 (Veeramani et al., 2005). This direct mechanism
seems unlikely, particularly since the cytoplasmic tail of ErbB2 is
not accessible to the active site of secretory PAP (which is
located extracellularly [Figure 1A] and in the lumen of vesicles).
Instead, PAP could indirectly regulate proliferation by generating
adenosine.
In support of this, there are four adenosine receptor subtypes,
with A1 and A3 coupled to inhibitory Gi-proteins and A2a and A2b
coupled to stimulatory Gq and Gs proteins (Jacobson and Gao,
2006). PAP could differentially modulate intracellular signaling
depending upon which adenosine receptor subtypes are ex-
pressed by cells. Notably, A3-adenosine receptors are found
on prostate cancer cells and A3-agonists inhibit the growth of
these cells (Fishman et al., 2003).
Adenosine regulates many other physiological processes
besides pain and cancer, including anxiety, inflammation, blood
pressure, pulmonary function, and renal function (Jacobson and
Gao, 2006). TM-PAP is expressed throughout the body (Quintero
et al., 2007). As such, TM-PAP could regulate diverse physiolog-
ical processes that are dependent on adenosine. Finally, our
study overturns the long-held belief that PAP is a generic ‘‘acid
phosphatase’’ by discovering a specific in vivo function for
PAP as an ectonucleotidase.
EXPERIMENTAL PROCEDURES
All procedures and behavioral experiments involving vertebrate animals were
approved by Institutional Animal Care and Use Committees at the University of
North Carolina at Chapel Hill and at the Universities of Oulu and Helsinki.
Molecular Biology
The full-length expression construct of PAP-transmembrane isoform (nt 64–
1317 from GenBank accession # NM_207668) was generated by RT-PCR
amplification, using C57BL/6mouse trigeminal cDNA as template and Phusion
polymerase. PCR products were cloned into pcDNA3.1 and completely se-
quenced. Isoform-specific in situ hybridization probes of PAP, secreted variant
(nt 1544–2625 from GenBank accession # NM_019807), and PAP, transmem-
brane variant (nt 1497–2577 from GenBank accession # NM_207668) were
generated by PCR amplification, using C57BL/6 mouse genomic DNA as
template and Phusion polymerase, then cloned into pBluescript-KS.
In situ hybridization was performed as described previously using digoxyge-
nin-labeled antisense and sense (control) riboprobes (Dong et al., 2001).
We confirmed that PAP was expressed in human DRG by performing
RT-PCR with RNA from human DRG (Clontech) and primers that spannedthree introns (exon 6 primer: 50 ctttcaggattacatggccagg; exon 9 primer:
50 cgtcaagtggcaagaagcatag).
Tissue Preparation
Adult male mice, 6–12 weeks of age, were sacrificed by cervical dislocation,
decapitation, or pentobarbital overdose. Lumbar spinal cord and DRG (L4–
L6) were dissected and then immersion fixed for 8 hr and 2 hr, respectively,
in 4% paraformaldehyde, 0.1 M phosphate buffer, pH 7.4. Tissues were cryo-
protected in 20% sucrose, 0.1M phosphate buffer, pH 7.3 at 4C for 24 hr, fro-
zen in OCT, sectioned with a cryostat at 15–20 mm, andmounted on Superfrost
Plus slides. Slides were stored at 20C. Free-floating sections were
sectioned at 30 mm and immediately stained.
Histology
Enzyme histochemistry was performed essentially as described by Shields
et al., with modifications suggested by Silverman and Kruger (Shields et al.,
2003; Silverman and Kruger, 1988a). Briefly, cells or tissue sections were
washed twice with 40 mM Trizma-Maleate (TM) buffer, pH 5.6, then once
with TM buffer containing 8% (w/v) sucrose. Samples were then incubated
at 37C for 2 hr in TM buffer containing 8% sucrose (w/v), 6 mM thiamine
monophosphate chloride or adenosine monophosphate (0.3 mM for tissue
sections, 6 mM for HEK293 cells), and 2.4 mM lead nitrate. Lead nitrate
must be made fresh immediately prior to use. To reduce nonspecific back-
ground staining, samples were washed once with 2% acetic acid for 1 min.
Samples were then washed three times with TM buffer, developed for 10 s
with 1% sodium sulfide, washed several times with PBS, pH 7.4, andmounted
in Gel/Mount (Biomeda). When assaying HEK293 cells using TMP or AMP
histochemistry, we stained duplicate samples with and without 0.1% Triton
X-100 in the initial TM wash. Images were acquired using a Zeiss Axioskop
and Olympus DP-71 camera.
Immunofluorescence was performed using antibodies and procedures
essentially as described (Zylka et al., 2005), although we substituted high
salt TBS + TX (50 mM Tris, 2.7% NaCl, 0.3% Triton X-100, pH 7.6) for
PBS + TX in all wash and antibody incubation steps. Additional antibodies in-
cluded 1:750 rabbit anti-CGRP (T-4032; Peninsula), 1:250 mouse anti-NeuN
(MAB377, Chemicon), 1:300 guinea pig anti-P2X3 (GP10108, Neuromics),
1:1000 goat anti-VR1 (sc-12498, Santa Cruz), and 1:1000 rabbit anti-human
PAP (Biomeda). We found that it was necessary to amplify the anti-PAP anti-
body signal by using secondary antibodies conjugated to biotin, then using
either 1:250 streptavidin-Cy3 (Jackson) or the Tyramide Signal Amplification
kit (New England Nuclear, following manufacturer’s protocol). Images were
obtained using a Leica TCS-NT confocal microscope.
Injections and Drugs
For intrathecal drug delivery, 5 ml was injected into unanesthetized mice using
the direct lumbar puncture method (Fairbanks, 2003). Human PAP (Sigma,
P1774, 100 U/ml) was dialyzed against 0.9% saline using Slide-A-Lyzer Mini
dialysis units (Pierce, 69576) for 4 hr at 4C. After dialysis, samples were di-
luted in 0.9% saline to a final concentration of 1.3 mg/ml (50 U/ml) and stored
at80C. hPAP was heat-inactivated by incubating at 65C for 40min. Bovine
prostatic acid phosphatase (bPAP, Sigma, P6409) was dissolved (aided by
sonication) in 0.9% saline to a final concentration of 30 mg/ml (0.3 U/ml).
Enzyme activity was quantified using the EnzChek Phosphatase Assay Kit
(Invitrogen, E12020) following the manufacturer’s protocol. Bovine serum al-
bumin (BSA, Sigma, A3912) was dissolved in 0.9% saline to a final concentra-
tion of 1.3 mg/ml. Recombinant bovine alkaline phosphatase was purchased
from Sigma (P8361, expressed in Pichia pastoris, >4000 U/mg protein). Mor-
phine sulfate (Sigma, M8777) and N6-cyclopentyladenosine (Sigma, C8031;
10 mM stock in dimethylsulfoxide; DMSO) were diluted into 0.9% saline. 8-cy-
clopentyl-1, 3-dipropylxanthine (C101, Sigma) was dissolved in 0.9% saline
containing 5% DMSO, 1.25% 1 M NaOH, and injected i.p.
Behavior
PAP/ and A1R
/mice were backcrossed to C57BL/6 mice (Jackson) for 10
and 12 generations, respectively. Isogenic wild-type mice were then derived
from the PAP/ line and used as wild-type controls. C57BL/6 male mice
were purchased from Jackson Laboratories for all behavioral experimentsNeuron 60, 111–122, October 9, 2008 ª2008 Elsevier Inc. 119
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4 months old, were used for all behavioral experiments. All mice were accli-
mated to the testing room, equipment, and experimenter for 1–3 days before
behavioral testing. The experimenter was blind to genotype and drug
treatment during behavioral testing.
Thermal sensitivity was measured by heating one hindpaw with a Plantar
Test apparatus (IITC) following the Hargreaves method (Hargreaves et al.,
1988). The radiant heat source intensity was calibrated so that a paw-with-
drawal reflex was evoked in 10 s., on average, in wild-type C57BL/6 mice.
Cutoff time was 20 s. One measurement was taken from each paw per day
to determine paw-withdrawal latency (with the exception of our morphine
and CPA dose-response experiments, which required multiple measurements
per day). To perform the tail-immersion assay, mice were gently restrained in
a towel and the distal one-third of the tail was immersed in 46.5C or 49C
water. Latency to withdrawal the tail was measured once per mouse. For the
hot plate test, mice were placed on ametal surface heated at 52C and latency
to jump, lick paws, or shake paws was measured. Mechanical sensitivity was
measured using semiflexible tips attached to an electronic von Frey apparatus
(IITC) as described elsewhere (Cunha et al., 2004; Inoue et al., 2004). Three
measurements were taken from each paw (separated at 10 min intervals)
then averaged to determine paw-withdrawal threshold in grams.
To induce inflammatory pain, 20 ml complete Freund’s adjuvant (CFA, from
Sigma or MP Biomedicals) was injected into one hindpaw, centrally beneath
glabrous skin, with a 30G needle. The spared nerve injury (SNI) model of
neuropathic pain was performed as described (Shields et al., 2003).
SUPPLEMENTAL DATA
The Supplemental Data include figures and tables and can be found with
this article online at http://www.neuron.org/supplemental/S0896-6273(08)
00750-2.
ACKNOWLEDGMENTS
We thank Edward Perl, Paul Farel, and Ben Philpot for comments on the man-
uscript; David J. Anderson for providingMrgprdDEGFPf mice; Stephen L. Tilley
for providing isogenic A1R
/ mice; Eduardo R. Lazarowski for measuring
adenosine and adenine nucleotides by HPLC; Shannon Shields and Allan I.
Basbaum for teaching us how to perform pain behavioral assays and SNI sur-
geries; and Yvette Chuang and Kunjumon Vadakkan for excellent technical as-
sistance. This work was supported by UNC startup funds, grants to M.J.Z.
from The Sloan Foundation, The Searle Scholars Program, The Klingenstein
Foundation, The Whitehall Foundation, Rita Allen Foundation, and NINDS
(R01NS060725), a grant to N.A.S. from NINDS (F30NS063507), and grants
to P.V. from The Sigrid Juselius Foundation, The Finnish Cancer Foundation,
and The Research Council for Medicine of the Academy of Finland. Confocal
imaging was performed at the UNC-CH Confocal Imaging Facility, which is co-
funded by NINDS and NICHD (P30NS045892). M.J.Z. is a Rita Allen Founda-
tion Milton E. Cassel Scholar.
M.J.Z. empirically determined that PAP was TMPase, conceived the work,
designed the experiments, supervised the project, and wrote the manuscript.
N.A.S. performed in situ hybridizations, phosphatase assays, intrathecal injec-
tions, and behavioral assays. B.T-B. performed histological experiments. M.T.
collected tissue for histology, performed intrathecal injections, SNI surgeries,
and behavioral assays. A.H. and P.V. generated and provided PAP knockout
mice and tissues. V.V. and P.V. conducted preliminary behavioral experiments
with PAP knockout mice. M.J.Z. and P.V. shared unpublished data to facilitate
this study.
Accepted: August 22, 2008
Published: October 8, 2008
REFERENCES
Belfrage, M., Segerdahl, M., Arner, S., and Sollevi, A. (1999). The safety and
efficacy of intrathecal adenosine in patients with chronic neuropathic pain.
Anesth. Analg. 89, 136–142.120 Neuron 60, 111–122, October 9, 2008 ª2008 Elsevier Inc.Burnstock, G. (2007). Physiology and pathophysiology of purinergic neuro-
transmission. Physiol. Rev. 87, 659–797.
Carr, P.A., Yamamoto, T., and Nagy, J.I. (1990). Calcitonin gene-related pep-
tide in primary afferent neurons of rat: co-existence with fluoride-resistant acid
phosphatase and depletion by neonatal capsaicin. Neuroscience 36, 751–760.
Colmant, H.J. (1959). Aktivitatsschwankungen der sauren Phosphatase im
Ruckenmark und den Spinalganglien der Ratte nach Durchschneidung des
Nervus ischiadicus. Arch. Psychiatr. Nervenkr. 199, 60–71.
Costigan, M., Befort, K., Karchewski, L., Griffin, R.S., D’Urso, D., Allchorne, A.,
Sitarski, J., Mannion, J.W., Pratt, R.E., and Woolf, C.J. (2002). Replicate high-
density rat genome oligonucleotide microarrays reveal hundreds of regulated
genes in the dorsal root ganglion after peripheral nerve injury. BMC Neurosci.
3, 16.
Csillik, B., and Knyihar-Csillik, E. (1986). The Protean Gate: Structure and
Plasticity of the Primary Nociceptive Analyzer (Budapest: Akademiai Kiado).
Cui, J.G., Sollevi, A., Linderoth, B., and Meyerson, B.A. (1997). Adenosine
receptor activation suppresses tactile hypersensitivity and potentiates spinal
cord stimulation in mononeuropathic rats. Neurosci. Lett. 223, 173–176.
Cunha, T.M., Verri, W.A., Jr., Vivancos, G.G., Moreira, I.F., Reis, S., Parada,
C.A., Cunha, F.Q., and Ferreira, S.H. (2004). An electronic pressure-meter
nociception paw test for mice. Braz. J. Med. Biol. Res. 37, 401–407.
Dalsgaard, C.J., Ygge, J., Vincent, S.R., Ohrling, M., Dockray, G.J., and Elde,
R. (1984). Peripheral projections and neuropeptide coexistence in a subpopu-
lation of fluoride-resistant acid phosphatase reactive spinal primary sensory
neurons. Neurosci. Lett. 51, 139–144.
Davis-Taber, R.A. (2006). Transcriptional profiling of dorsal root ganglia in
a neuropathic pain model using microarray and laser capture microdissection.
Drug Dev. Res. 67, 308–330.
Dirig, D.M., and Yaksh, T.L. (1995). Differential right shifts in the dose-response
curve for intrathecal morphine and sufentanil as a function of stimulus inten-
sity. Pain 62, 321–328.
Dodd, J., Jahr, C.E., Hamilton, P.N., Heath, M.J., Matthew, W.D., and Jessell,
T.M. (1983). Cytochemical and physiological properties of sensory and dorsal
horn neurons that transmit cutaneous sensation. Cold Spring Harb. Symp.
Quant. Biol. 48, 685–695.
Dong, X., Han, S., Zylka, M.J., Simon, M.I., and Anderson, D.J. (2001). A
diverse family of GPCRs expressed in specific subsets of nociceptive sensory
neurons. Cell 106, 619–632.
Dziembor-Gryszkiewicz, E., Fikus, M., Kazimierczuk, Z., and Ostrowski, W.
(1978). Activity of human prostatic acid phosphatase toward purine 50-phos-
phonucleosides. Bull. Acad. Pol. Sci. Biol. 26, 815–821.
Eisenach, J.C., Hood, D.D., and Curry, R. (2002). Preliminary efficacy assess-
ment of intrathecal injection of an American formulation of adenosine in
humans. Anesthesiology 96, 29–34.
Fairbanks, C.A. (2003). Spinal delivery of analgesics in experimental models of
pain and analgesia. Adv. Drug Deliv. Rev. 55, 1007–1041.
Fishman, P., Bar-Yehuda, S., Ardon, E., Rath-Wolfson, L., Barrer, F., Ochaion,
A., and Madi, L. (2003). Targeting the A3 adenosine receptor for cancer ther-
apy: inhibition of prostate carcinoma cell growth by A3AR agonist. Anticancer
Res. 23, 2077–2083.
Gomes, J.A., Li, X., Pan, H.L., and Eisenach, J.C. (1999). Intrathecal adenosine
interacts with a spinal noradrenergic system to produce antinociception in
nerve-injured rats. Anesthesiology 91, 1072–1079.
Grant, G.J., Cascio, M., Zakowski, M.I., Langerman, L., and Turndorf, H.
(1995). Intrathecal administration of liposomal morphine in a mouse model.
Anesth. Analg. 81, 514–518.
Gutman, A.B., and Gutman, E.B. (1938). An ‘‘acid’’ phosphatase occurring in
the serum of patients with metastasizing carcinoma of the prostate gland.
J. Clin. Invest. 17, 473–478.
Hargreaves, K., Dubner, R., Brown, F., Flores, C., and Joris, J. (1988). A new
and sensitive method for measuring thermal nociception in cutaneous
hyperalgesia. Pain 32, 77–88.
Neuron
PAP Suppresses Pain by Generating AdenosineHayashida, M., Fukuda, K., and Fukunaga, A. (2005). Clinical application of
adenosine and ATP for pain control. J. Anesth. 19, 225–235.
Hua, X., Erikson, C.J., Chason, K.D., Rosebrock, C.N., Deshpande, D.A.,
Penn, R.B., and Tilley, S.L. (2007). Involvement of A1 adenosine receptors
and neural pathways in adenosine-induced bronchoconstriction in mice.
Am. J. Physiol. Lung Cell. Mol. Physiol. 293, L25–L32.
Hunt, S.P., and Rossi, J. (1985). Peptide- and non-peptide-containing unmy-
elinated primary afferents: the parallel processing of nociceptive information.
Philos. Trans. R. Soc. Lond. B Biol. Sci. 308, 283–289.
Hunt, S.P., and Mantyh, P.W. (2001). The molecular dynamics of pain control.
Nat. Rev. Neurosci. 2, 83–91.
Inoue, M., Rashid, M.H., Fujita, R., Contos, J.J., Chun, J., and Ueda, H. (2004).
Initiation of neuropathic pain requires lysophosphatidic acid receptor signal-
ing. Nat. Med. 10, 712–718.
Jacobson, K.A., and Gao, Z.G. (2006). Adenosine receptors as therapeutic
targets. Nat. Rev. Drug Discov. 5, 247–264.
Johansson, B., Halldner, L., Dunwiddie, T.V., Masino, S.A., Poelchen, W.,
Gimenez-Llort, L., Escorihuela, R.M., Fernandez-Teruel, A., Wiesenfeld-Hallin,
Z., Xu, X.J., et al. (2001). Hyperalgesia, anxiety, and decreased hypoxic neuro-
protection in mice lacking the adenosine A1 receptor. Proc. Natl. Acad. Sci.
USA 98, 9407–9412.
Knyihar-Csillik, E., Bezzegh, A., Boti, S., and Csillik, B. (1986). Thiaminemono-
phosphatase: a genuine marker for transganglionic regulation of primary
sensory neurons. J. Histochem. Cytochem. 34, 363–371.
Lao, L.J., Kumamoto, E., Luo, C., Furue, H., and Yoshimura, M. (2001). Aden-
osine inhibits excitatory transmission to substantia gelatinosa neurons of the
adult rat spinal cord through the activation of presynaptic A(1) adenosine
receptor. Pain 94, 315–324.
Lavand’homme, P.M., and Eisenach, J.C. (1999). Exogenous and endogenous
adenosine enhance the spinal antiallodynic effects of morphine in a rat model
of neuropathic pain. Pain 80, 31–36.
Lazarowski, E.R., Tarran, R., Grubb, B.R., van Heusden, C.A., Okada, S., and
Boucher, R.C. (2004). Nucleotide release provides a mechanism for airway
surface liquid homeostasis. J. Biol. Chem. 279, 36855–36864.
Lee, Y.W., and Yaksh, T.L. (1996). Pharmacology of the spinal adenosine
receptor which mediates the antiallodynic action of intrathecal adenosine
agonists. J. Pharmacol. Exp. Ther. 277, 1642–1648.
Li, J., and Perl, E.R. (1994). Adenosine inhibition of synaptic transmission in the
substantia gelatinosa. J. Neurophysiol. 72, 1611–1621.
Li, J., and Perl, E.R. (1995). ATP modulation of synaptic transmission in the
spinal substantia gelatinosa. J. Neurosci. 15, 3357–3365.
Li, H.C., Chernoff, J., Chen, L.B., and Kirschonbaum, A. (1984). A phospho-
tyrosyl-protein phosphatase activity associated with acid phosphatase from
human prostate gland. Eur. J. Biochem. 138, 45–51.
Lin, M.F., DaVolio, J., and Garcia-Arenas, R. (1992). Expression of human
prostatic acid phosphatase activity and the growth of prostate carcinoma
cells. Cancer Res. 52, 4600–4607.
Liu, X.J., and Salter, M.W. (2005). Purines and pain mechanisms: recent devel-
opments. Curr. Opin. Investig. Drugs 6, 65–75.
Maione, S., de Novellis, V., Cappellacci, L., Palazzo, E., Vita, D., Luongo, L.,
Stella, L., Franchetti, P., Marabese, I., Rossi, F., and Grifantini, M. (2007).
The antinociceptive effect of 2-chloro-20-C-methyl-N6-cyclopentyladenosine
(20-Me-CCPA), a highly selective adenosine A1 receptor agonist, in the rat.
Pain 131, 281–292.
McMahon, S.B., and Moore, C.E. (1988). Plasticity of primary afferent acid
phosphatase expression following rerouting of afferents from muscle to skin
in the adult rat. J. Comp. Neurol. 274, 1–8.
Meng, T.C., and Lin, M.F. (1998). Tyrosine phosphorylation of c-ErbB-2 is reg-
ulated by the cellular form of prostatic acid phosphatase in human prostate
cancer cells. J. Biol. Chem. 273, 22096–22104.Nagy, J.I., and Hunt, S.P. (1982). Fluoride-resistant acid phosphatase-contain-
ing neurones in dorsal root ganglia are separate from those containing
substance P or somatostatin. Neuroscience 7, 89–97.
Nagy, J.I., and Daddona, P.E. (1985). Anatomical and cytochemical relation-
ships of adenosine deaminase-containing primary afferent neurons in the
rat. Neuroscience 15, 799–813.
Nakagawa, T., Wakamatsu, K., Zhang, N., Maeda, S., Minami, M., Satoh, M.,
and Kaneko, S. (2007). Intrathecal administration of ATP produces long-lasting
allodynia in rats: differential mechanisms in the phase of the induction and
maintenance. Neuroscience 147, 445–455.
Nishiyama, T., Ho, R.J., Shen, D.D., and Yaksh, T.L. (2000). The effects of in-
trathecal morphine encapsulated in L- and D-dipalmitoylphosphatidyl choline
liposomes on acute nociception in rats. Anesth. Analg. 91, 423–428.
Ostrowski, W.S., and Kuciel, R. (1994). Human prostatic acid phosphatase:
selected properties and practical applications. Clin. Chim. Acta 226, 121–129.
Patel, M.K., Pinnock, R.D., and Lee, K. (2001). Adenosine exerts multiple
effects in dorsal horn neurones of the adult rat spinal cord. Brain Res. 920,
19–26.
Patterson, S.L., Sluka, K.A., and Arnold, M.A. (2001). A novel transverse push-
pull microprobe: in vitro characterization and in vivo demonstration of the en-
zymatic production of adenosine in the spinal cord dorsal horn. J. Neurochem.
76, 234–246.
Poon, A., and Sawynok, J. (1998). Antinociception by adenosine analogs and
inhibitors of adenosine metabolism in an inflammatory thermal hyperalgesia
model in the rat. Pain 74, 235–245.
Porvari, K.S., Herrala, A.M., Kurkela, R.M., Taavitsainen, P.A., Lindqvist, Y.,
Schneider, G., and Vihko, P.T. (1994). Site-directed mutagenesis of prostatic
acid phosphatase. Catalytically important aspartic acid 258, substrate speci-
ficity, and oligomerization. J. Biol. Chem. 269, 22642–22646.
Post, C. (1984). Antinociceptive effects in mice after intrathecal injection of
50-N-ethylcarboxamide adenosine. Neurosci. Lett. 51, 325–330.
Quintero, I.B., Araujo, C.L., Pulkka, A.E., Wirkkala, R.S., Herrala, A.M., Eskeli-
nen, E.L., Jokitalo, E., Hellstrom, P.A., Tuominen, H.J., Hirvikoski, P.P., and
Vihko, P.T. (2007). Prostatic acid phosphatase is not a prostate specific target.
Cancer Res. 67, 6549–6554.
Roiko, K., Janne, O.A., and Vihko, P. (1990). Primary structure of rat secretory
acid phosphatase and comparison to other acid phosphatases. Gene 89,
223–229.
Salter, M.W., and Henry, J.L. (1985). Effects of adenosine 50-monophosphate
and adenosine 50-triphosphate on functionally identified units in the cat spinal
dorsal horn. Evidence for a differential effect of adenosine 50-triphosphate on
nociceptive vs non-nociceptive units. Neuroscience 15, 815–825.
Sanyal, S., and Rustioni, A. (1974). Phosphatases in the substantia gelatinosa
and motoneurones: a comparative histochemical study. Brain Res. 76,
161–166.
Sawynok, J. (2006). Adenosine and ATP receptors. Handb. Exp. Pharmacol.
177, 309–328.
Schulte, G., Robertson, B., Fredholm, B.B., DeLander, G.E., Shortland, P., and
Molander, C. (2003). Distribution of antinociceptive adenosine A1 receptors in
the spinal cord dorsal horn, and relationship to primary afferents and neuronal
subpopulations. Neuroscience 121, 907–916.
Scott, T.G. (1967). The distribution of 50-nucleotidase in the brain of themouse.
J. Comp. Neurol. 129, 97–114.
Shields, S.D., Eckert, W.A., 3rd, and Basbaum, A.I. (2003). Spared nerve injury
model of neuropathic pain in the mouse: a behavioral and anatomic analysis.
J. Pain 4, 465–470.
Silverman, J.D., and Kruger, L. (1988a). Acid phosphatase as a selective
marker for a class of small sensory ganglion cells in several mammals: spinal
cord distribution, histochemical properties, and relation to fluoride-resistant
acid phosphatase (FRAP) of rodents. Somatosens. Res. 5, 219–246.
Silverman, J.D., and Kruger, L. (1988b). Lectin and neuropeptide labeling of
separate populations of dorsal root ganglion neurons and associatedNeuron 60, 111–122, October 9, 2008 ª2008 Elsevier Inc. 121
Neuron
PAP Suppresses Pain by Generating Adenosine‘‘nociceptor’’ thin axons in rat testis and cornea whole-mount preparations.
Somatosens. Res. 5, 259–267.
Silverman, J.D., and Kruger, L. (1990). Selective neuronal glycoconjugate
expression in sensory and autonomic ganglia: relation of lectin reactivity to
peptide and enzyme markers. J. Neurocytol. 19, 789–801.
Suran, A.A. (1974). 50-Nucleotidase and an acid phosphatase of spinal cord.
Comparative histochemistry and specificity of the enzymes in mouse and
cat spinal cords. Cytologic localization in mouse substantia gelatinosa.
J. Histochem. Cytochem. 22, 802–811.
Tanaka, M., Kishi, Y., Takanezawa, Y., Kakehi, Y., Aoki, J., and Arai, H. (2004).
Prostatic acid phosphatase degrades lysophosphatidic acid in seminal
plasma. FEBS Lett. 571, 197–204.
Tenser, R.B. (1985). Sequential changes of sensory neuron (fluoride-resistant)
acid phosphatase in dorsal root ganglion neurons following neurectomy and
rhizotomy. Brain Res. 332, 386–389.
Tenser, R.B., Viselli, A.L., and Savage, D.H. (1991). Reversible decrease of
fluoride resistant acid phosphatase-positive neurons after herpes simplex
virus infection. Neurosci. Lett. 130, 85–88.
Tozaki-Saitoh, H., Tsuda, M., Miyata, H., Ueda, K., Kohsaka, S., and Inoue, K.
(2008). P2Y12 receptors in spinal microglia are required for neuropathic pain
after peripheral nerve injury. J. Neurosci. 28, 4949–4956.
Tsuda, M., Inoue, K., and Salter, M.W. (2005). Neuropathic pain and spinal
microglia: a big problem from molecules in ‘‘small’’ glia. Trends Neurosci.
28, 101–107.
Van Etten, R.L. (1982). Human prostatic acid phosphatase: a histidine phos-
phatase. Ann. N Y Acad. Sci. 390, 27–51.122 Neuron 60, 111–122, October 9, 2008 ª2008 Elsevier Inc.Veeramani, S., Yuan, T.C., Chen, S.J., Lin, F.F., Petersen, J.E., Shaheduzza-
man, S., Srivastava, S., MacDonald, R.G., and Lin, M.F. (2005). Cellular
prostatic acid phosphatase: a protein tyrosine phosphatase involved in andro-
gen-independent proliferation of prostate cancer. Endocr. Relat. Cancer 12,
805–822.
Vihko, P. (1978). Characterization of the principal human prostatic acid phos-
phatase isoenzyme, purified by affinity chromatography and isoelectric focus-
ing. Part II. Clin. Chem. 24, 1783–1787.
Vihko, P. (1979). Human prostatic acid phosphatases: purification of a minor
enzyme and comparisons of the enzymes. Invest. Urol. 16, 349–352.
Vihko, P., Schroeder, F.H., Lukkarinen, O., and Vihko, R. (1982). Secretion into
and elimination from blood circulation of prostate specific acid phosphatase,
measured by radioimmunoassay. J. Urol. 128, 202–204.
Woolf, C.J., and Ma, Q. (2007). Nociceptors—noxious stimulus detectors.
Neuron 55, 353–364.
Wu, W.P., Hao, J.X., Halldner, L., Lovdahl, C., DeLander, G.E., Wiesenfeld-
Hallin, Z., Fredholm, B.B., and Xu, X.J. (2005). Increased nociceptive response
in mice lacking the adenosine A1 receptor. Pain 113, 395–404.
Zhang, Y., Conklin, D.R., Li, X., and Eisenach, J.C. (2005). Intrathecal morphine
reduces allodynia after peripheral nerve injury in rats via activation of a spinal
A1 adenosine receptor. Anesthesiology 102, 416–420.
Zimmermann, H. (2006). Ectonucleotidases in the nervous system. Novartis
Found. Symp. 276, 113–128.
Zylka, M.J., Rice, F.L., and Anderson, D.J. (2005). Topographically distinct epi-
dermal nociceptive circuits revealed by axonal tracers targeted to Mrgprd.
Neuron 45, 17–25.
